HRP20171993T1 - Varijante ljudskog gdnf - Google Patents
Varijante ljudskog gdnf Download PDFInfo
- Publication number
- HRP20171993T1 HRP20171993T1 HRP20171993TT HRP20171993T HRP20171993T1 HR P20171993 T1 HRP20171993 T1 HR P20171993T1 HR P20171993T T HRP20171993T T HR P20171993TT HR P20171993 T HRP20171993 T HR P20171993T HR P20171993 T1 HRP20171993 T1 HR P20171993T1
- Authority
- HR
- Croatia
- Prior art keywords
- variant
- seq
- rgqrgkqrgcvltaihlnvtdlglgyetkeelifrycsgscdaaettyd
- human gdnf
- gdnf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- External Artificial Organs (AREA)
Claims (11)
1. Varijanta ljudskog GDNF, naznačena time što ima aminokiselinski slijed SEQ ID NO: 23:
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD
KILXaa84NLSXaa88NXaa90RLVSEKVGQACCRPIAFDDDLSFLDDNLVYHI
LRXaa125HSAKXaa130CGCI
gdje:
i) Xaa84 je K ili A;
ii) Xaa88 je R ili K;
iii) Xaa90 je R ili K;
iv) Xaa125 je K ili E; i
v) Xaa130 je R ili E.
2. Varijanta ljudskog GDNF u skladu s patentnim zahtjevom 1, naznačena time što se navedenu varijantu bira iz skupine koju čine
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD
KILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK
RCGCI (SEQ ID NO: 9),
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD
KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK
RCGCI (SEQ ID NO: 12),
i
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD
KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILREHSAK
ECGCI (SEQ ID NO: 15).
3. Varijanta ljudskog GDNF u skladu s patentnim zahtjevom 2, naznačena time što je navedena varijanta
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD
KILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK
RCGCI (SEQ. ID: 9).
4. Varijanta ljudskog GDNF u skladu s patentnim zahtjevom 2, naznačena time što je navedena varijanta
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD
KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK
RCGCI (SEQ ID NO: 12).
5. Varijanta ljudskog GDNF u skladu s patentnim zahtjevom 2, naznačena time što je navedena varijanta
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD
KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILREHSAK
ECGCI (SEQ ID NO: 15).
6. Međuprodukt , naznačen time što je namijenjen dobivanju Δ31-N-terminalne skraćene varijante GDNF koja sadrži aminokiselinski slijed koji se bira iz skupine koju čine
METDTLLLVVVLLLVVVPGSTGRGQRGKQRGCVLTAIHLNVTDLGLGYET
KEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDD
DLSFLDDNL VYHILRKHSAKRCGCI (SEQ ID NO: 28);
i
MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDL
GLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACC
RPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID NO: 35).
7. Međuprodukt u skladu s patentnim zahtjevom 6, naznačen time što je aminokiselinski slijed
MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDL
GLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRL VSEKVGQACC
RPIAFDDDLSFLDDNL VYHILRKHSAKRCGCI (SEQ ID NO: 35).
8. Farmaceutski pripravak, naznačen time što sadrži varijantu ljudskog GDNF u skladu s bilo kojim od patentnih zahtjeva 1 do 5, kao i jedan ili više farmaceutski prihvatljivih razrjeđivača, podloga ili pomoćnih tvari.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je namijenjen upotrebi u liječenju Parkinsonove bolesti kod ljudskog pacijenta.
10. Varijanta ljudskog GDNF u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što je namijenjena upotrebi kao medikament.
11. Varijanta ljudskog GDNF u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što je namijenjena upotrebi u liječenju Parkinsonove bolesti.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474024P | 2011-04-11 | 2011-04-11 | |
| EP12712874.2A EP2696889B1 (en) | 2011-04-11 | 2012-04-03 | Variants of human gdnf |
| PCT/US2012/031927 WO2012141936A1 (en) | 2011-04-11 | 2012-04-03 | Variants of human gdnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171993T1 true HRP20171993T1 (hr) | 2018-02-09 |
Family
ID=45932578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171993TT HRP20171993T1 (hr) | 2011-04-11 | 2012-04-03 | Varijante ljudskog gdnf |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9243046B2 (hr) |
| EP (1) | EP2696889B1 (hr) |
| JP (1) | JP6093345B2 (hr) |
| KR (1) | KR101554799B1 (hr) |
| CN (1) | CN103635201B (hr) |
| AU (1) | AU2012243178B2 (hr) |
| BR (1) | BR112013026004B1 (hr) |
| CA (1) | CA2833158C (hr) |
| CY (1) | CY1119750T1 (hr) |
| DK (1) | DK2696889T3 (hr) |
| EA (1) | EA025129B1 (hr) |
| ES (1) | ES2656020T3 (hr) |
| HR (1) | HRP20171993T1 (hr) |
| HU (1) | HUE036239T2 (hr) |
| IL (1) | IL228102A (hr) |
| LT (1) | LT2696889T (hr) |
| ME (1) | ME02849B (hr) |
| MX (1) | MX337206B (hr) |
| NO (1) | NO2696889T3 (hr) |
| PL (1) | PL2696889T3 (hr) |
| PT (1) | PT2696889T (hr) |
| RS (1) | RS56639B1 (hr) |
| SG (1) | SG193483A1 (hr) |
| SI (1) | SI2696889T1 (hr) |
| TW (1) | TWI583698B (hr) |
| UA (1) | UA112981C2 (hr) |
| WO (1) | WO2012141936A1 (hr) |
| ZA (1) | ZA201306556B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018073300A2 (pt) | 2016-05-13 | 2019-03-26 | Instituto De Medicina Molecular | métodos para tratamento de doenças associadas com as células ilc3 |
| WO2021119827A1 (en) * | 2019-12-19 | 2021-06-24 | Transfert Plus, Société En Commandite | Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies |
| JP2024522938A (ja) | 2021-06-03 | 2024-06-21 | フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド | 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9205293A (es) | 1991-09-20 | 1993-05-01 | Syntex Sinergen Neuroscience J | Factores neurotrofico derivado del glial |
| US6184200B1 (en) * | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
| US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
| US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
| FI20070808A0 (fi) * | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
| CN101775072B (zh) * | 2008-05-21 | 2012-09-05 | 王尚武 | 一种融合穿透肽的神经细胞营养因子gdnf |
| CA2751445C (en) * | 2009-02-06 | 2018-06-19 | Pepscan Systems B.V. | Truncated cystine-knot proteins |
-
2012
- 2012-03-04 UA UAA201311714A patent/UA112981C2/uk unknown
- 2012-03-27 TW TW101110653A patent/TWI583698B/zh active
- 2012-04-03 HU HUE12712874A patent/HUE036239T2/hu unknown
- 2012-04-03 US US14/000,704 patent/US9243046B2/en active Active
- 2012-04-03 MX MX2013011919A patent/MX337206B/es active IP Right Grant
- 2012-04-03 EA EA201370204A patent/EA025129B1/ru not_active IP Right Cessation
- 2012-04-03 NO NO12712874A patent/NO2696889T3/no unknown
- 2012-04-03 SI SI201231134T patent/SI2696889T1/en unknown
- 2012-04-03 BR BR112013026004-1A patent/BR112013026004B1/pt not_active IP Right Cessation
- 2012-04-03 CA CA2833158A patent/CA2833158C/en not_active Expired - Fee Related
- 2012-04-03 ES ES12712874.2T patent/ES2656020T3/es active Active
- 2012-04-03 AU AU2012243178A patent/AU2012243178B2/en not_active Ceased
- 2012-04-03 KR KR1020137026366A patent/KR101554799B1/ko not_active Expired - Fee Related
- 2012-04-03 EP EP12712874.2A patent/EP2696889B1/en active Active
- 2012-04-03 ME MEP-2017-276A patent/ME02849B/me unknown
- 2012-04-03 PL PL12712874T patent/PL2696889T3/pl unknown
- 2012-04-03 PT PT127128742T patent/PT2696889T/pt unknown
- 2012-04-03 WO PCT/US2012/031927 patent/WO2012141936A1/en not_active Ceased
- 2012-04-03 HR HRP20171993TT patent/HRP20171993T1/hr unknown
- 2012-04-03 JP JP2014505179A patent/JP6093345B2/ja active Active
- 2012-04-03 CN CN201280018010.7A patent/CN103635201B/zh active Active
- 2012-04-03 DK DK12712874.2T patent/DK2696889T3/en active
- 2012-04-03 LT LTEP12712874.2T patent/LT2696889T/lt unknown
- 2012-04-03 RS RS20171274A patent/RS56639B1/sr unknown
- 2012-04-03 SG SG2013069554A patent/SG193483A1/en unknown
-
2013
- 2013-08-22 IL IL228102A patent/IL228102A/en active IP Right Grant
- 2013-08-30 ZA ZA2013/06556A patent/ZA201306556B/en unknown
-
2018
- 2018-01-09 CY CY20181100021T patent/CY1119750T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| JP2013520405A5 (hr) | ||
| JP2014530220A5 (hr) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2015057451A5 (hr) | ||
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| JP2015517488A5 (hr) | ||
| JP2012041342A5 (hr) | ||
| MX2012004625A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. | |
| EA201101518A1 (ru) | Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии | |
| SI2709613T1 (en) | Procedures for the treatment of HCV | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| BR112015010396A2 (pt) | terapia de combinação | |
| MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| EA201591701A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| HRP20191723T1 (hr) | Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa | |
| EA201500513A1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
| HRP20171993T1 (hr) | Varijante ljudskog gdnf | |
| EP4389218A3 (en) | Composition for treating joint disease and kit containing same | |
| AR093476A1 (es) | Composiciones y metodos para el tratamiento de la displasia ectodermica | |
| EA200970562A1 (ru) | Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы |